Aldosterone Synthase Inhibitor for CKD

Award Information
Agency:
Department of Health and Human Services
Amount:
$380,911.00
Program:
SBIR
Contract:
1R43DK095625-01A1
Solitcitation Year:
2013
Solicitation Number:
PA12-088
Branch:
N/A
Award Year:
2013
Phase:
Phase I
Agency Tracking Number:
R43DK095625
Solicitation Topic Code:
NIDDK
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd, Uniondale, NY, -
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
53129065
Principal Investigator
 BERT OEHLEN
 (516) 326-1200
 boehlen@angion.com
Business Contact
 BERT OEHLEN
Phone: (516) 326-1200
Email: boehlen@angion.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): The renin-angiotensin-aldosterone system (RAAS) plays a critical role in renal physiology. Inhibitors of angiotensin-converting enzyme (ACE) or angiotensin receptor blockers (ARB) are the mainstay in the clinical management of renal disorders such as chronic kidney disease (CKD). These treatments are thought to work in large part by reducing serum and renal aldosterone levels. However, despite initial success of ACE inhibition or ARB therapy to reduce aldosterone, levelseventually often return to pretreatment levels, thus limiting therapeutic effectiveness of RAAS inhibitors. The clinical significance of th phenomenon of aldosterone breakthrough is increasingly recognized. One approach to combat this breakthrough is toinhibit the enzyme responsible for aldosterone production: aldosterone synthase. Despite promising results of tool aldosterone synthase inhibitors in preclinical animal models, no aldosterone synthase inhibitors are currently undergoing clinical evaluation for CKD. From a focused library, Angion has identified a new series of proprietary non- steroidal small molecule inhibitors of aldosterone synthase. The present grant proposal aims to (1) optimize this series of compounds and (2) test efficacy in preclinical models of renal fibrosis. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The renin-angiotensin-aldosterone system (RAAS) plays a critical role in renal physiology. The direct patho- physiological role of aldosterone in the etiolgy of chronic kidney disease is increasingly recognized. Current inhibitors of the RAAS system are effective in reducing aldosterone, but levels are eventually often found to return to pretreatment levels, thus limiting therapeutic effectiveness such RAAS inhibitors. It is thought that aldosterone breakthrough can be prevented or corrected by directly inhibiting the enzyme aldosterone synthase. Angion has identified a new series of proprietary non-steroidal small molecule inhibitors of aldosterone synthase, whichit seeks to further develop into effective therapeutics for chronic kidney disease.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government